We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Dare Bioscience Inc | NASDAQ:DARE | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.0164 | -4.97% | 0.3135 | 0.3134 | 0.3194 | 0.33 | 0.313 | 0.316 | 207,248 | 15:32:21 |
|
x
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
☐
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Large Accelerated Filer
|
|
o
|
|
Accelerated filer
|
o
|
Non-accelerated filer
|
|
x
|
|
Smaller reporting company
|
x
|
Emerging growth company
|
|
x
|
|
|
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock
|
DARE
|
Nasdaq Capital Market
|
|
•
|
Inability to continue as a going concern;
|
•
|
Inability to raise additional capital, under favorable terms or at all;
|
•
|
Inability to successfully attract partners and enter into collaborations on acceptable terms;
|
•
|
Failure to select or capitalize on the most scientifically, clinically or commercially promising or profitable indications or therapeutic areas for our product candidates due to limited financial resources;
|
•
|
Inability to develop and commercialize our product candidates;
|
•
|
Failure or delay in starting, conducting and completing clinical trials or obtaining United States Food and Drug Administration, or FDA, or foreign regulatory approval for our product candidates in a timely manner;
|
•
|
A change in the FDA’s primary oversight responsibility;
|
•
|
A change in regulatory requirements for our product candidates, including the development pathway pursuant to Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act, or the FDA's 505(b)(2) pathway;
|
•
|
Unsuccessful clinical trial outcomes stemming from clinical trial designs, failure to enroll a sufficient number of patients, higher than anticipated patient dropout rates, failure to meet established clinical endpoints, undesirable side effects and other safety concerns;
|
•
|
Negative publicity concerning the safety and efficacy of our product candidates, or of product candidates being developed by others that share characteristics similar to our candidates;
|
•
|
Inability to demonstrate sufficient efficacy of our product candidates;
|
•
|
Loss of our licensed rights to develop and commercialize a product candidate as a result of the termination of the underlying licensing agreement;
|
•
|
Monetary obligations and other requirements in connection with our exclusive, in-license agreements covering the patents and related intellectual property related to our product candidates;
|
•
|
Developments by our competitors that make our product candidates less competitive or obsolete;
|
•
|
Dependence on third parties to conduct clinical trials and to manufacture product candidates;
|
•
|
Dependence on third parties to supply clinical supplies and raw materials, drugs and other materials required to produce a finished product and to produce the quantities needed;
|
•
|
Failure of our product candidates, if approved, to gain market acceptance or obtain adequate coverage for third party reimbursement;
|
•
|
A reduction in demand for contraceptives caused by an elimination of current requirements that health insurance plans cover and reimburse FDA-cleared or approved contraceptive products without cost sharing;
|
•
|
Lack of precedent to help assess whether health insurance plans will cover our product candidates;
|
•
|
The reimbursement environment relating to our product candidates at the time we obtain regulatory approval, if ever;
|
•
|
Difficulty in introducing branded products in a market made up of generic products;
|
•
|
Inability to adequately protect or enforce our, or our licensor’s, intellectual property rights;
|
•
|
Lack of patent protection for the active ingredients in certain of our product candidates which could expose those product candidates to competition from other formulations using the same active ingredients;
|
•
|
Higher risk of failure associated with product candidates in pre-clinical stages of development that may lead investors to assign them little to no value and make these assets difficult to fund;
|
•
|
Disputes or other developments concerning our intellectual property rights;
|
•
|
Actual and anticipated fluctuations in our quarterly or annual operating results;
|
•
|
Price and volume fluctuations in the stock market, and in our stock in particular, which could subject us to securities class-action litigation;
|
•
|
Litigation or public concern about the safety of our potential products;
|
•
|
Strict government regulations on our business, including various fraud and abuse laws, including, without limitation, the U.S. federal Anti-Kickback Statute, the U.S. federal False Claims Act and the U.S. Foreign Corrupt Practices Act;
|
•
|
Regulations governing the production or marketing of our product candidates;
|
•
|
Loss of, or inability to attract, key personnel; and
|
•
|
Increased costs as a result of operating as a public company, and substantial time devoted by our management to compliance initiatives and corporate governance practices.
|
|
|
Page
|
|
||
|
|
|
Item 1.
|
||
|
|
|
Item 2.
|
||
|
|
|
Item 3.
|
||
|
|
|
Item 4.
|
||
|
|
|
|
||
|
|
|
Item 1.
|
||
|
|
|
Item 1A.
|
||
|
|
|
Item 2.
|
||
|
|
|
Item 3.
|
||
|
|
|
Item 4.
|
||
|
|
|
Item 5.
|
||
|
|
|
Item 6.
|
||
|
|
|
|
PART I.
|
FINANCIAL INFORMATION
|
|
March 31,
2019 |
|
December 31,
2018 |
||||
|
(unaudited)
|
|
|
||||
Assets
|
|
|
|
||||
Current assets
|
|
|
|
||||
Cash and cash equivalents
|
$
|
3,505,026
|
|
|
$
|
6,805,889
|
|
Other receivables
|
166,713
|
|
|
31,037
|
|
||
Prepaid expenses
|
588,524
|
|
|
403,097
|
|
||
Total current assets
|
4,260,263
|
|
|
7,240,023
|
|
||
Property and equipment, net
|
8,245
|
|
|
9,396
|
|
||
Other non-current assets
|
751,347
|
|
|
577,968
|
|
||
Total assets
|
$
|
5,019,855
|
|
|
$
|
7,827,387
|
|
Liabilities and stockholders’ equity
|
|
|
|
||||
Current liabilities
|
|
|
|
||||
Accounts payable
|
$
|
325,618
|
|
|
$
|
459,705
|
|
Accrued expenses
|
690,829
|
|
|
631,351
|
|
||
Total current liabilities
|
1,016,447
|
|
|
1,091,056
|
|
||
Other liabilities
|
223,039
|
|
|
9,711
|
|
||
Total liabilities
|
1,239,486
|
|
|
1,100,767
|
|
||
Commitments and contingencies (Note 8)
|
|
|
|
|
|
||
Stockholders' equity
|
|
|
|
||||
Preferred stock, $0.01 par value, 5,000,000 shares authorized; None issued and outstanding
|
—
|
|
|
—
|
|
||
Common stock, $0.0001 par value; 120,000,000 shares authorized; 11,422,161 shares issued and outstanding each period
|
1,143
|
|
|
1,143
|
|
||
Accumulated other comprehensive loss
|
(89,107
|
)
|
|
(96,728
|
)
|
||
Additional paid-in capital
|
35,889,940
|
|
|
35,791,972
|
|
||
Accumulated deficit
|
(32,021,607
|
)
|
|
(28,969,767
|
)
|
||
Total stockholders' equity
|
3,780,369
|
|
|
6,726,620
|
|
||
Total liabilities and stockholders' equity
|
$
|
5,019,855
|
|
|
$
|
7,827,387
|
|
|
Three months ended March 31,
|
||||||
|
2019
|
|
2018
|
||||
Operating expenses
|
|
|
|
||||
General and administrative
|
$
|
1,277,180
|
|
|
$
|
1,303,189
|
|
Research and development expenses
|
1,693,391
|
|
|
1,086,653
|
|
||
License expenses
|
112,500
|
|
|
100,000
|
|
||
Impairment of goodwill
|
—
|
|
|
5,187,519
|
|
||
Total operating expenses
|
3,083,071
|
|
|
7,677,361
|
|
||
Loss from operations
|
(3,083,071
|
)
|
|
(7,677,361
|
)
|
||
Other income
|
31,231
|
|
|
11,744
|
|
||
Net loss
|
$
|
(3,051,840
|
)
|
|
$
|
(7,665,617
|
)
|
Foreign currency translation adjustments
|
$
|
7,621
|
|
|
$
|
(13,746
|
)
|
Comprehensive loss
|
$
|
(3,044,219
|
)
|
|
$
|
(7,679,363
|
)
|
Loss per common share - basic and diluted
|
$
|
(0.27
|
)
|
|
$
|
(0.88
|
)
|
Weighted average number of common shares outstanding:
|
|
|
|
||||
Basic and diluted
|
11,422,161
|
|
|
8,684,550
|
|
Three Months Ended March 31, 2019
|
||||||||||||||||||||||
|
|
|
|
|
Additional
|
|
Accumulated
other |
|
|
|
Total
|
|||||||||||
|
Common stock
|
|
paid-in
|
|
comprehensive
|
|
Accumulated
|
|
stockholders'
|
|||||||||||||
|
Shares
|
|
Amount
|
|
capital
|
|
loss
|
|
deficit
|
|
equity
|
|||||||||||
Balance at December 31, 2018
|
11,422,161
|
|
|
$
|
1,143
|
|
|
$
|
35,791,972
|
|
|
$
|
(96,728
|
)
|
|
$
|
(28,969,767
|
)
|
|
$
|
6,726,620
|
|
Stock-based compensation
|
—
|
|
|
—
|
|
|
97,968
|
|
|
—
|
|
|
—
|
|
|
97,968
|
|
|||||
Net loss
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(3,051,840
|
)
|
|
(3,051,840
|
)
|
|||||
Foreign currency translation adjustments
|
—
|
|
|
—
|
|
|
—
|
|
|
7,621
|
|
|
—
|
|
|
7,621
|
|
|||||
Balance at March 31, 2019
|
11,422,161
|
|
|
$
|
1,143
|
|
|
$
|
35,889,940
|
|
|
$
|
(89,107
|
)
|
|
$
|
(32,021,607
|
)
|
|
$
|
3,780,369
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
Three Months Ended March 31, 2018
|
||||||||||||||||||||||
|
|
|
|
|
Additional
|
|
Accumulated
other |
|
|
|
Total
|
|||||||||||
|
Common stock
|
|
paid-in
|
|
comprehensive
|
|
Accumulated
|
|
stockholders'
|
|||||||||||||
|
Shares
|
|
Amount
|
|
capital
|
|
loss
|
|
deficit
|
|
equity
|
|||||||||||
Balance at December 31, 2017
|
6,047,161
|
|
|
$
|
605
|
|
|
$
|
25,541,210
|
|
|
$
|
(18,080
|
)
|
|
$
|
(12,230,952
|
)
|
|
$
|
13,292,783
|
|
Stock-based compensation
|
—
|
|
|
—
|
|
|
9,124
|
|
|
—
|
|
|
—
|
|
|
9,124
|
|
|||||
Net proceeds from issuance of common stock and warrants
|
375,000
|
|
|
37
|
|
|
1,037,727
|
|
|
—
|
|
|
—
|
|
|
1,037,764
|
|
|||||
Issuance of common stock via public offering, net
|
5,000,000
|
|
|
500
|
|
|
9,159,548
|
|
|
—
|
|
|
—
|
|
|
9,160,048
|
|
|||||
Net loss
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(7,665,617
|
)
|
|
(7,665,617
|
)
|
|||||
Foreign currency translation adjustments
|
—
|
|
|
—
|
|
|
—
|
|
|
(13,746
|
)
|
|
—
|
|
|
(13,746
|
)
|
|||||
Balance at March 31, 2018
|
11,422,161
|
|
|
$
|
1,142
|
|
|
$
|
35,747,609
|
|
|
$
|
(31,826
|
)
|
|
$
|
(19,896,569
|
)
|
|
$
|
15,820,356
|
|
|
Three months ended March 31,
|
||||||
|
2019
|
|
2018
|
||||
Operating activities:
|
|
|
|
||||
Net loss
|
$
|
(3,051,840
|
)
|
|
$
|
(7,665,617
|
)
|
Non-cash adjustments reconciling net loss to operating cash flows:
|
|
|
|
||||
Depreciation
|
1,150
|
|
|
—
|
|
||
Stock-based compensation
|
97,968
|
|
|
9,124
|
|
||
Non-cash lease expenses
|
10,130
|
|
|
—
|
|
||
Impairment of goodwill
|
—
|
|
|
5,187,519
|
|
||
Changes in operating assets and liabilities:
|
|
|
|
||||
Other receivables
|
(135,676
|
)
|
|
255,318
|
|
||
Prepaid expenses
|
(201,129
|
)
|
|
20,694
|
|
||
Other current assets
|
—
|
|
|
193,495
|
|
||
Other non-current assets and deferred charges
|
55,233
|
|
|
37,131
|
|
||
Accounts payable
|
(134,087
|
)
|
|
(40,340
|
)
|
||
Accrued expenses
|
59,478
|
|
|
(118,707
|
)
|
||
Other liabilities
|
(9,711
|
)
|
|
2,496
|
|
||
Net cash used in operating activities
|
(3,308,484
|
)
|
|
(2,118,887
|
)
|
||
Financing activities:
|
|
|
|
||||
Net proceeds from issuance of common stock and warrants
|
—
|
|
|
10,197,813
|
|
||
Net cash provided by financing activities
|
—
|
|
|
10,197,813
|
|
||
Effect of exchange rate changes on cash and cash equivalents
|
7,621
|
|
|
(13,746
|
)
|
||
Net change in cash and cash equivalents
|
(3,300,863
|
)
|
|
8,065,180
|
|
||
Cash and cash equivalents, beginning of period
|
6,805,889
|
|
|
7,559,846
|
|
||
Cash and cash equivalents, end of period
|
$
|
3,505,026
|
|
|
$
|
15,625,026
|
|
Supplemental disclosure of non-cash operating activities:
|
|
|
|
||||
Operating right-of-use assets obtained in exchange for new operating lease liabilities
|
$
|
231,698
|
|
|
$
|
—
|
|
|
|
|
|
1.
|
ORGANIZATION AND DESCRIPTION OF THE BUSINESS
|
•
|
DARE-BV1, a unique hydrogel formulation of clindamycin phosphate 2% to treat bacterial vaginosis, or BV;
|
•
|
Ovaprene, a non-hormonal monthly contraceptive intravaginal ring;
|
•
|
Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil to treat female sexual arousal disorder, or FSAD; and
|
•
|
DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for hormone replacement therapy following menopause.
|
•
|
DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy, or VVA, in patients with hormone-receptor positive breast cancer;
|
•
|
DARE-RH1, a novel approach to non-hormonal contraception for both men and women by targeting the CatSper ion channel;
|
•
|
ORB-204 and ORB-214, 6-month and 12-month formulations of injectable etonogestrel for contraception;
|
•
|
DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and for fertility support as part of an
in vitro
fertilization, or IVF, treatment plan; and
|
•
|
DARE-OAB1, an intravaginal ring containing oxybutynin for the treatment of overactive bladder.
|
2.
|
GOING CONCERN
|
3.
|
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
|
•
|
Level 1: inputs are unadjusted quoted prices in active markets for identical assets or liabilities.
|
•
|
Level 2: inputs other than level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of assets or liabilities.
|
•
|
Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
|
4.
|
ACQUISITIONS
|
Purchase Consideration
|
(in thousands)
|
||
Fair value of shares issued
|
$
|
20,625
|
|
Unamortized fair value of Cerulean options
|
3,654
|
|
|
Fair value of total consideration
|
$
|
24,279
|
|
Assets acquired and liabilities assumed
|
|
||
Cash and cash equivalents
|
$
|
9,918
|
|
Prepaid expense and other current assets
|
1,915
|
|
|
Accounts payable
|
(233
|
)
|
|
Total assets acquired and liabilities assumed
|
11,600
|
|
|
Goodwill
|
$
|
12,679
|
|
5.
|
STOCK-BASED COMPENSATION
|
|
Number of Shares
|
|
Weighted Average
Exercise Price
|
|||
Outstanding at December 31, 2018 (1)
|
1,635,790
|
|
|
$
|
11.08
|
|
Granted
|
563,000
|
|
|
0.76
|
|
|
Exercised
|
—
|
|
|
—
|
|
|
Canceled/forfeited
|
(8,360
|
)
|
|
17.81
|
|
|
Expired
|
(70
|
)
|
|
59.48
|
|
|
Outstanding at March 31, 2019 (unaudited) (1)
|
2,190,360
|
|
|
$
|
8.40
|
|
Exercisable at March 31, 2019 (unaudited)
|
650,151
|
|
|
$
|
25.97
|
|
|
Three Months Ended
March 31, |
||||||
|
2019
|
|
2018
|
||||
Research and development
|
$
|
24,703
|
|
|
$
|
—
|
|
General and administrative
|
73,265
|
|
|
9,124
|
|
||
Total
|
$
|
97,968
|
|
|
$
|
9,124
|
|
|
|
Three Months Ended
March 31, 2019 |
Expected life in years
|
|
10.0
|
Risk-free interest rate
|
|
2.70%
|
Expected volatility
|
|
120%
|
Forfeiture rate
|
|
0.0%
|
Dividend yield
|
|
0.0%
|
Weighted-average fair value of options granted
|
|
$0.72
|
6.
|
STOCKHOLDERS’ EQUITY
|
Shares Underlying
Outstanding Warrants
|
|
Exercise Price
|
|
Expiration Date
|
||
2,906
|
|
$
|
120.40
|
|
|
December 1, 2021
|
3,737
|
|
$
|
120.40
|
|
|
December 6, 2021
|
17,190
|
|
$
|
60.50
|
|
|
January 8, 2020
|
6,500
|
|
$
|
10.00
|
|
|
April 4, 2026
|
3,720,500
|
|
$
|
3.00
|
|
|
February 15, 2023
|
3,750,833
|
|
|
|
|
7.
|
LEASED PROPERTIES
|
Years ending December 31:
|
|
||
Remainder of 2019
|
$
|
81,950
|
|
2020
|
112,943
|
|
|
2021
|
67,595
|
|
|
Total future minimum lease payments
|
262,488
|
|
|
Less: Difference between future minimum lease payments and discounted operating lease liabilities
|
39,449
|
|
|
Total operating lease liabilities
|
$
|
223,039
|
|
8.
|
COMMITMENTS AND CONTINGENCIES
|
9.
|
GRANT AWARD
|
10.
|
NET LOSS PER SHARE
|
Potentially dilutive securities
|
|
Three months ended
March 31, |
||||
|
|
2019
|
|
2018
|
||
Stock options
|
|
2,190,360
|
|
|
543,396
|
|
Warrants
|
|
3,750,833
|
|
|
3,751,002
|
|
Total
|
|
5,941,193
|
|
|
4,294,398
|
|
11.
|
SUBSEQUENT EVENTS
|
•
|
DARE-BV1, a unique hydrogel formulation of clindamycin phosphate 2% for bacterial vaginosis, or BV;
|
•
|
Ovaprene®, a non-hormonal monthly contraceptive intravaginal ring;
|
•
|
Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil for female sexual arousal disorder, or FSAD; and
|
•
|
DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for hormone replacement therapy, or HRT, following menopause.
|
•
|
DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy, or VVA, in patients with hormone-receptor positive breast cancer;
|
•
|
DARE-RH1, a novel approach to non-hormonal contraception for both men and women by targeting the CatSper ion channel;
|
•
|
ORB-204 and ORB-214, 6-month and 12-month formulations of injectable etonogestrel for contraception;
|
•
|
DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and for fertility support as part of an IVF treatment plan; and
|
•
|
DARE-OAB1, an intravaginal ring containing oxybutynin for the treatment of overactive bladder.
|
•
|
expenses incurred under agreements with consultants and clinical trial sites that conduct research and development activities on our behalf;
|
•
|
laboratory and vendor expenses related to the execution of clinical trials;
|
•
|
contract manufacturing expenses, primarily for the production of clinical supplies;
|
•
|
transaction costs related to the acquisition of technologies and related intellectual property; and
|
•
|
internal costs that are associated with activities performed by our research and development organization and generally benefit multiple programs.
|
|
Three months ended March 31,
|
|
Dollar
|
||||||||
|
2019
|
|
2018
|
|
Change
|
||||||
Operating expenses:
|
|
|
|
|
|
||||||
General and administrative expense
|
$
|
1,277,180
|
|
|
$
|
1,303,189
|
|
|
$
|
(26,009
|
)
|
Research and development expenses
|
1,693,391
|
|
|
1,086,653
|
|
|
606,738
|
|
|||
License expenses
|
112,500
|
|
|
100,000
|
|
|
12,500
|
|
|||
Impairment of goodwill
|
—
|
|
|
5,187,519
|
|
|
(5,187,519
|
)
|
|||
Total operating expenses
|
3,083,071
|
|
|
7,677,361
|
|
|
(4,594,290
|
)
|
|||
Loss from operations
|
(3,083,071
|
)
|
|
(7,677,361
|
)
|
|
4,594,290
|
|
|||
Other income
|
31,231
|
|
|
11,744
|
|
|
19,487
|
|
|||
Net loss
|
(3,051,840
|
)
|
|
(7,665,617
|
)
|
|
4,613,777
|
|
|||
Other comprehensive loss:
|
|
|
|
|
|
|
|||||
Foreign currency translation adjustments
|
7,621
|
|
|
(13,746
|
)
|
|
21,367
|
|
|||
Comprehensive loss
|
$
|
(3,044,219
|
)
|
|
$
|
(7,679,363
|
)
|
|
$
|
4,635,144
|
|
|
Three months ended March 31,
|
||||||
|
2019
|
|
2018
|
||||
Net cash used in operating activities
|
(3,308,484
|
)
|
|
(2,118,887
|
)
|
||
Net cash provided by financing activities
|
—
|
|
|
10,197,813
|
|
||
Effect of exchange rate changes on cash and cash equivalents
|
7,621
|
|
|
(13,746
|
)
|
||
Net increase (decrease) in cash
|
$
|
(3,300,863
|
)
|
|
$
|
8,065,180
|
|
|
|
|
|
Incorporated by Reference
|
|
|
|
|
||||
Exhibit
Number
|
|
Description of Exhibit
|
|
Form
|
|
File No.
|
|
Filing Date
|
|
Exhibit No.
|
|
Filed Herewith
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31.1
|
|
|
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31.2
|
|
|
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
32.1
|
|
|
|
|
|
|
|
|
|
|
#
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
32.2
|
|
|
|
|
|
|
|
|
|
|
#
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
101.INS
|
|
XBRL Instance Document
|
|
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
|
101.SCH
|
|
XBRL Taxonomy Extension Schema Document
|
|
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
|
101.CAL
|
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
|
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
|
101.DEF
|
|
XBRL Taxonomy Extension Definition Linkbase Document
|
|
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
|
101.LAB
|
|
XBRL Taxonomy Extension Label Linkbase Document
|
|
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
|
101.PRE
|
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
|
|
|
|
|
|
|
|
|
X
|
|
|
Daré Bioscience, Inc.
|
|
|
|
Date: May 14, 2019
|
By:
|
/s/ Sabrina Martucci Johnson
|
|
|
Sabrina Martucci Johnson
|
|
|
President and Chief Executive Officer
|
|
|
(Principal Executive Officer)
|
|
|
|
Date: May 14, 2019
|
By:
|
/s/ Lisa Walters-Hoffert
|
|
|
Lisa Walters-Hoffert
|
|
|
Chief Financial Officer
|
|
|
(Principal Financial and Accounting Officer)
|
1 Year Dare Bioscience Chart |
1 Month Dare Bioscience Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions